Skip to main content

Table 4 Relationship between drug allocation and age and gender in patients who survived more than 30 days.

From: Use of evidence-based pharmacotherapy after myocardial infarction in Estonia

Drug Male
OR
(95% CI)
Female
OR
(95% CI)
20-39 years
OR
(95% CI)
40-59 years
OR
(95% CI)
60-79 years
OR
(95% CI)
80-99 years
OR
(95% CI)
BB 1.00 0.79
(0.61-1.02)
1.00 0.56
(0.17-1.91)
0.97
(0.29-3.19)
1.93
(0.58-6.47)
ACE/ARB 1.00 0.89
(0.70-1.14)
  1.00 2.49
(1.67-3.70)**
5.69
(3.66-8.82)**
Statins 1.00 1.19
(0.55-2.57)
  1.00 0.88
(0.38-2.06)
0.17
(0.02-1.37)
BB & ACE/ARB 1.00 1.15
(0.99-1.33)
1.00 0.79
(0.37-1.70)
1.21
(0.57-2.57)
1.92
(0.89-4.14)
BB & statins 1.00 0.68
(0.49-0.92)**
1.00 0.66
(0.19-2.21)
0.81
(0.24-2.66)
0.28
(0.08-1.06)
ACE/ARB & statins 1.00 0.63
(0.44-0.89)**
1.00 0.48
(0.18-1.28)
0.32
(0.12-0.84)**
0.19
(0.06-0.58)**
BB & ACE/ARB & statins 1.00 1.21
(1.05-1.39)**
1.00 1.94
(1.00-3.77)
1.02
(0.53-1.96)
0.28
(0.14-0.55)**
  1. **P < 0.05 by logistic regression method.
  2. BB, beta-blockers; ACE/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; OR, Odds ratio; CI, confidence interval